Advertisement
"We are pleased to welcome Mr. Glorikian and Ms. Tuttle to the GeneNewsBoard of Directors. Mr. Glorikian is currently the managing partner ofScientia Advisors, an international management and strategy consulting firmwith a concentration in biotechnology and life sciences and Ms. Tuttle isPresident and Chief Executive Officer of HX Diagnostics, a diagnostics companyin Emeryville, Ca., specialising in rapid diagnostics for seasonal andemerging infectious diseases," said K. Wayne Marshall, MD, PhD, President andChief Executive Officer of GeneNews. "Their extensive experience in moleculardiagnostics makes them timely additions to our Board as we prepare for thecommercialization of our laboratory developed test (LDT) version ofColonSentry(TM), a blood-based molecular test to assess current risk forcolorectal cancer. We expect to launch ColonSentry in Canada in the thirdquarter of this year."
Advertisement
Prior to becoming the Managing Partner at Scientia Advisors, Mr. Glorikianspent more than 8 years at Applied Biosystems in various roles, completing histenure as Senior Manager, New Technology Assessment/Business Development. Hewas also the National Sales Manager for Signet Laboratories and a founder ofX-Cell Laboratories, a clinical reference laboratory in San Francisco.
Ms. Tuttle is currently the President and CEO of HX Diagnostics.Throughout her career, she has developed and launched several majordiagnostics products and had corporate experience at leading diagnosticcompanies including Bayer, Corning, Inc., Novartis, and Chiron. Ms. Tuttle wasa Senior Vice President at Bayer Diagnostics responsible for a worldwidebusiness of $400M. Most recently Ms. Tuttle was President and CEO ofProtedyne, Inc., a robotics company developing automation solutions formolecular diagnostics and drug discovery, which was sold to LabCorp in 2007.
About GeneNews
--------------
GeneNews is focused on the application of functional genomics to enableearly diagnosis and personalized therapeutic intervention based ondisease-specific biomarkers. The Company has developed a novel approach, theSentinel Principle(TM), to detect and stage virtually any disease or medicalcondition from a simple blood sample. GeneNews is currently applying theSentinel Principle(TM) in major areas with unmet clinical needs such ascancer, arthritis, cardiovascular disease and neurological disorders.GeneNews' first product in development, ColonSentry(TM), is a convenient andpatient-friendly blood-based test that can assess an individual's current riskfor colorectal cancer. For more information on GeneNews, visitwww.genenews.com.
This press release contains forward-looking statements, which reflect theCompany's current expectations regarding future events. The forward-lookingstatements involve risks and uncertainties. Actual events could differmaterially from those projected herein. Investors should consult the Company'songoing quarterly filings and annual reports for additional information onrisks and uncertainties relating to these forward-looking statements. Thereader is cautioned not to rely on these forward-looking statements. TheCompany disclaims any obligation to update these forward-looking statements.
SOURCE GeneNews Limited
